Streetbeat News

Regulatory

ANVS

Annovis Bio's stock is rising following FDA clearance for Phase 3 Alzheimer's studies and alignment of Buntanetap NDAs.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 1:24 pm

GOOG

GOOGL

OKLO

Oklo Inc (NYSE:OKLO) shares are rising due to momentum from a Google nuclear deal and the U.S. Department of Energy's approval of Oklo's Aurora fuel fabrication facility design report. This positions Oklo for future advancements in nuclear energy.

Portfolio Pulse from Adam Eckert

October 15, 2024 | 1:16 pm

LTRN

Lantern Pharma shares rose after the FDA granted fast-track designation to LP-184 for Glioblastoma treatment.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 1:14 pm

LTRN

Lantern Pharma's drug candidate LP-184 has received FDA Fast-Track designation for the treatment of glioblastoma, a type of brain cancer. This designation is expected to expedite the development and review process of LP-184, potentially bringing it to market faster.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 1:08 pm

ALGS

Aligos Therapeutics has announced that abstracts on incremental data from their ALG-000184 in chronic hepatitis B (CHB) subjects and a late-breaker oral presentation of data from the Phase 2a HERALD study of ALG-055009 in metabolic-associated steatohepatitis (MASH) subjects have been accepted at the Liver Meeting 2024.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 1:08 pm

SEEL

Seelos Therapeutics has received a delisting notice from Nasdaq and will transfer its listing to the Over-the-Counter market.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 1:03 pm

SGD

Safe and Green Development has completed site work and secured permits for its South Texas Sugar Phase I project. The company plans to begin construction soon and aims to deliver 35 homes by Q1 2025.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 12:58 pm

IMRX

Immuneering's shares rose following the FDA's orphan drug designation for IMM-1-104, a treatment for pancreatic cancer.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 12:55 pm

C

Citigroup's CFO, Mark Mason, reported 'good progress' on the company's simplification and regulatory efforts during a media call, though he acknowledged that more work remains to be done.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 12:54 pm

SLS

SELLAS Life Sciences shares rose after the company received FDA rare pediatric disease designation for its drug Galinpepimut-S, aimed at treating pediatric acute myeloid leukemia.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 12:48 pm